Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ALXN closed down 1.09 percent on Friday, August 17, 2018, on 79 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical ALXN trend table...|
|Date||Alert Name||Type||% Chg|
|Aug 17||Inside Day||Range Contraction||0.00%|
|Aug 17||Oversold Stochastic||Weakness||0.00%|
|Aug 16||Oversold Stochastic||Weakness||-1.09%|
|Aug 15||Downside 200 DMA Break||Bearish||0.59%|
|Aug 15||Oversold Stochastic||Weakness||0.59%|
|Aug 14||Upside 200 DMA Break||Bullish||-3.07%|
|Aug 14||Multiple of Ten Bearish||Other||-3.07%|
|Aug 14||Oversold Stochastic||Weakness||-3.07%|
|Aug 13||200 DMA Resistance||Bearish||-2.00%|
|Aug 13||NR7||Range Contraction||-2.00%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ALXN news...
|52 Week High||149.34|
|52 Week Low||102.1|
|200-Day Moving Average||118.9153|
|50-Day Moving Average||126.2576|
|20-Day Moving Average||125.7155|
|10-Day Moving Average||119.177|
|Average True Range||3.1552|
|Chandelier Exit (Long, 3 ATRs )||129.3044|
|Chandelier Exit (Short, 3 ATRs )||123.8656|
|Upper Bollinger Band||140.4551|
|Lower Bollinger Band||110.9759|
|Percent B (%b)||0.17|
|MACD Signal Line||-2.1989|
|Market Cap||25.89 Billion|
|Num Shares||223 Million|
|Price-to-Earnings (P/E) Ratio||50.22|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||118.75|
|Resistance 3 (R3)||118.87||118.07||118.29|
|Resistance 2 (R2)||118.07||117.37||118.01||118.13|
|Resistance 1 (R1)||117.04||116.94||116.64||116.92||117.98|
|Support 1 (S1)||115.21||115.54||114.81||115.09||114.02|
|Support 2 (S2)||114.41||115.11||114.35||113.87|
|Support 3 (S3)||113.38||114.41||113.71|
|Support 4 (S4)||113.26|